A positive 2021, with growing numbers and which saw investments of 22 million euros in Italy. To say the report “Boehringer Ingelheim for Italy” created by Kpmg and presented today in Milan during the event that celebrated the 50th anniversary of the company in Italy. In 2021 Boehringer Ingelheim invested 22 million euros in Italy, of which 5 million in clinical trials, with increasing investments in production centers.
Last year the company generated a direct, indirect and induced added value for Italy of 276 million euros, with a concrete and positive impact on GDP (for each euro of direct, indirect and induced added value, 0.99 euros of GDP) and with a virtuous circle also in terms of employment: for each Boehringer Ingelheim employee 2 jobs were created throughout the country, for a total of 3,143 jobs activated.
Boehringer Ingelheim Italia participates in 43% of clinical trials launched globally and in 47% of research projects that have reached phase 3. It is present in 130 markets and in 2021 it invested 4.1 billion in R&D (+11.7 % compared to 2020) and net turnover was 20.6 billion (+ 5.4% compared to 2020), with the company planning to invest over 25 billion euros in Research & Development over the next five years.
«Over the last 50 years, Boehringer Ingelheim Italia has grown to become a reality of almost 1,000 employees with two production sites. Since our foundation we have been operating with the aim of growing together with the country, with a view to partnership and with constant attention to mutual value. This is the spirit with which we look to the future, with the aim of continuing to bring value to the community and contribute to a more sustainable tomorrow for the next generations ”the words of Morena Sangiovanni, president of Boehringer Ingelheim Italia.
Last year, the German pharmaceutical company saw the enhancement of the pipeline and many medical advances including 3 Breakthrough Therapy designations granted by the US FDA to innovative drugs in the Human Pharma sector. The company also plans to invest over 25 billion euros in Research & Development globally over the next five years; capital expenditures are foreseen for new production technologies and a state-of-the-art supply network, with investments of over 7 billion euros. The goal is to support and accelerate Human Pharma’s pipeline, which could lead to 15 new product launches by 2025.